Corcept Therapeutics

Corcept Therapeutics

Employees:
100
Market Cap:
$1.69 billion
Revenue:
$81.16 million
Net Income:
$13.5 million
NASDAQ:
CORT

Corcept Therapeutics Inc. has developed treatments mainly focusing on solving metabolic disorders and related problems, and have several experimental and on-sale drugs released. One of the principle drugs that the company has been developing is Korlym, which is an oral daily medication for patients with type II diabetes mellitus or glutose intolerance, and those who failed or might not be appropriate to be under surgery. Wikipedia

Corcept Therapeutics

Employees:
100
Market Cap:
$1.69 billion
Revenue:
$81.16 million
Net Income:
$13.5 million
NASDAQ:
CORT

Corcept Therapeutics Inc. has developed treatments mainly focusing on solving metabolic disorders and related problems, and have several experimental and on-sale drugs released. One of the principle drugs that the company has been developing is Korlym, which is an oral daily medication for patients with type II diabetes mellitus or glutose intolerance, and those who failed or might not be appropriate to be under surgery. Wikipedia